Gastrointestinal Cancer
Gastrointestinal (GI) cancer is characterized by abnormal, malignant cell growth in the GI tract and accessory organs of digestion, including the esophagus, stomach, biliary system, pancreas, intestines, rectum, and anus. Diagnosis typically involves endoscopy and biopsy, with symptoms and treatment varying based on the cancer's location, type, and extent of spread.
Health Outcomes
- Altered Faecal Microbiota Profile
- Attenuated Apoptosis
- Colonization of Gastrointestinal Tract by L. reuteri
- Elevated Fecal Acidic Steroid Levels
- Elevated β-Catenin Levels in Intestinal Stem Cells
- Enhanced Diversity of Protective Bifidobacterial Populations
- Enhanced GLP-2 Secretion
- Enhanced Tumor-Targeted Drug Delivery
- Ensured Safety for Human Consumption
- Gastrointestinal Survival
- Improved Chemotherapy Efficacy
- Improved Colorectal Cancer Outcomes
- Improved Gastrointestinal Survival
- Improved Intestinal Crypt Survival
- Improved Intestinal Survival
- Improved Microenvironment
- Improved Overall Survival
- Improved Proliferative Capacity of Intestinal Cells
- Improved Response to Immune Checkpoint Inhibitor Therapy
- Improved Secondary Outcomes
- Improved Survival Rate in Digestive Conditions
- Improved Survival Through Digestive Tract
- Improved Survival Through GI Passage
- Improved Survival Through Gastric Conditions
- Improved Survival Under Gastrointestinal Challenges
- Improved Survival Under Gastrointestinal Conditions
- Improved Survival in Digestive Environment
- Improved Survival in Gastroduodenal Environment
- Increased Activation of Intestinal Stem Cells
- Increased Bacillus Species
- Increased Cellular Adhesion
- Increased Crypt Depth
- Increased Fecal Immunological Biomarkers
- Increased Gastric Epithelial Stem/Progenitor Cell Proliferation
- Increased Gastric Survival Rate
- Increased Hydrolyzed Fumonisin B1 Conversion
- Increased Intestinal Stem Cell Proliferation
- Increased Intratumoral Accumulation
- Increased Lgr5 Levels in Intestinal Epithelium
- Increased Polyamine Production
- Increased Tissue Invasion
- Induced Glycolysis Pathway in Gastrointestinal Tract
- Lack of Long-Term Colonization of Bifidobacteria Strains
- Maintained Intestinal Microbiota Balance
- Maintained Viability in Presence of Bile Salts
- Modulated Intestinal Metabolite Profile
- Modulated Intestinal Microbial Community
- Modulated Intestinal Microbial Taxa
- Modulation of Colon Epithelium by Lactate
- No Change in Gastrointestinal Survival
- No Improvement in Objective Cancer Treatment Response
- No Significant Change in Gastrointestinal Symptoms
- Non-Toxicity to Normal Colon Cells
- Protection Against Induced Colon Cancer
- Protection Against Intestinal Epithelial Injury
- Reduced Acute Radiation Enteritis Severity
- Reduced Apoptosis of Colon Epithelial Cells
- Reduced Apoptosis of Jejunal Mucosal Cells
- Reduced Bowel Toxicity-Related Hospital Care
- Reduced CEA Levels
- Reduced Cancer-Related Inflammation
- Reduced Carcinogenesis
- Reduced Carcinogenic Activity of Intestinal Flora
- Reduced Chemotherapy-Induced Diarrhea
- Reduced Epithelial-Mesenchymal Transition
- Reduced Fecal Hydrogen Sulfide Emissions
- Reduced Ferritin Level
- Reduced Foodborne Pathogen Load
- Reduced Fumonisin B1 Levels
- Reduced Gastric Epithelial Proliferation Signaling
- Reduced Gastric Polyamine Levels
- Reduced Gastric Tissue Damage
- Reduced Gastrointestinal Toxicity
- Reduced Genera Romboutsia
- Reduced Harmful Intestinal Metabolites
- Reduced Intestinal Apoptosis
- Reduced Intestinal Epithelial Apoptosis
- Reduced Pathological Characteristics of the Intestinal Tract
- Reduced Radiological Damage in the Gut
- Reduced Risk of Gastrointestinal Cancer
- Reduced Serum Albumin Levels
- Reduced Tumor Downstaging
- Regulated Gut Microbiota Metabolic Function
- Shifted Tumor-Associated Macrophages Toward Pro-Inflammatory M1 Polarization
- Suppressed H. pylori Growth In Vivo